Osteomyelitis—infection of the bone—is one of the most consequential complications of the diabetic foot. It is present in a substantial proportion of moderate-to-severe diabetic foot infections, and its recognition changes how a wound is managed: the length of antibiotic therapy, whether surgery is needed, and ultimately the risk to the limb. Because bone infection often hides beneath an unremarkable-looking ulcer, and because diabetic neuropathy blunts the usual warning sign of pain, diabetic foot osteomyelitis (DFO) is frequently diagnosed late. This article reviews what current evidence and international guidelines say about diagnosing and treating it.
Recognizing Bone Infection in the Diabetic Foot
No single test reliably confirms or excludes DFO, so clinicians rely on a combination of bedside, laboratory, and imaging findings. The 2023 guidelines from the International Working Group on the Diabetic Foot (IWGDF) and the Infectious Diseases Society of America (IDSA) recommend beginning with the probe-to-bone test, plain radiographs, and an inflammatory marker such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), or procalcitonin. A positive probe-to-bone test—in which a sterile blunt probe reaches hard, gritty bone at the base of an ulcer—substantially raises the likelihood of osteomyelitis in a patient at high risk, while a negative test in a low-risk patient helps rule it out.
Plain X-rays are inexpensive and widely available but change slowly; the bony destruction that confirms infection may not appear for two to three weeks. When the diagnosis remains uncertain, magnetic resonance imaging (MRI) is the imaging test of choice, offering high sensitivity and specificity (roughly 90% and 83% in pooled analyses) and helping define the extent of infection and any associated soft-tissue abscess. Markedly elevated inflammatory markers, a persistently non-healing ulcer over bone, and a “sausage toe” appearance all add to the clinical picture.
The Value of Bone Biopsy and Culture
Whenever feasible and safe, a bone sample provides the most accurate guide to treatment. Samples taken directly from bone are more reliable than superficial swabs, which are frequently contaminated by skin flora and can mislead antibiotic choices. In a retrospective analysis of patients with DFO, culture data from bone biopsy or deep tissue changed antibiotic management in 87% of patients, most often allowing therapy to be narrowed to a more targeted agent, and revealing that a meaningful subset could be switched to a highly bioavailable oral regimen (Hockney et al., 2022). Obtaining tissue for both culture and histopathology also improves diagnostic certainty, since inflammatory and imaging findings alone can be ambiguous.
Antibiotics, Surgery, or Both?
Historically, DFO was treated with amputation, but evidence over the past decade has shown that many cases—particularly forefoot infections without extensive bone destruction, without peripheral arterial disease, and without exposed necrotic bone—can be managed successfully with antibiotics alone. Surgery remains important when there is spreading infection, a large abscess, mechanical instability, or dead bone that will not respond to medical therapy. The decision is best made by a multidisciplinary team, and reviews consistently emphasize that combining infectious disease, podiatric, and surgical expertise improves outcomes and reduces unnecessary treatment (Nauriyal & Byers, 2025).
Duration of therapy has also been refined. Current guidance suggests approximately six weeks of antibiotics when infected bone is treated without resection, and a much shorter course—on the order of three weeks—when infected bone is surgically removed, such as after a minor amputation, leaving only residual or soft-tissue infection. Ongoing randomized trials continue to test whether even shorter courses are non-inferior, with the goal of reducing antibiotic exposure and adverse events (Waibel et al., 2020).
Oral Versus Intravenous Antibiotics
A longstanding assumption held that bone infection required prolonged intravenous antibiotics. That view has shifted. Studies now suggest that oral agents with good bone penetration and bioavailability are not inferior to intravenous therapy for many patients with DFO. In one single-center comparison of 128 patients with residual osteomyelitis after amputation (excluding those with peripheral arterial disease), treatment success did not differ significantly between oral and intravenous regimens, and oral therapy offered advantages in cost and convenience (Kipp et al., 2024). Oral options can spare patients the risks and burden of long-term intravenous access, though the choice still depends on the organism, its susceptibilities, and the patient’s circulation and comorbidities.
Key Takeaways
Diabetic foot osteomyelitis is common, easily missed, and highly consequential. Diagnosis rests on integrating the probe-to-bone test, plain radiographs, inflammatory markers, and—when needed—MRI, with bone biopsy providing the most reliable microbiological guidance. Treatment has moved away from routine amputation toward individualized care: selected cases respond to antibiotics alone, surgery is reserved for clear indications, therapy durations are shorter than once believed, and oral antibiotics are a reasonable option for many patients. Above all, the evidence points to early recognition and coordinated, multidisciplinary management as central to preserving the limb.
References
Senneville É, et al. Diagnosis and treatment of diabetes-related foot infections (IWGDF/IDSA 2023). Clinical Infectious Diseases, 2023.
Nauriyal V, Byers K. Diabetic foot infections: questions for an infectious disease consultant. Seminars in Vascular Surgery, 2025.
Kipp JA, LeSavage LK, Evans JK, Denmeade TA, Blazek CD. Diabetic osteomyelitis: oral versus intravenous antibiotics at a single Level 1 academic medical trauma center. The Journal of Foot and Ankle Surgery, 2024;63(4):490–494.
Hockney SM, Steker D, Bhasin A, Krueger KM, Williams J, Galvin S. Role of bone biopsy and deep tissue culture for antibiotic stewardship in diabetic foot osteomyelitis. Journal of Antimicrobial Chemotherapy, 2022;77(12):3482–3486.
Waibel F, Berli M, Catanzaro S, et al. Optimization of the antibiotic management of diabetic foot infections: protocol for two randomized controlled trials. Trials, 2020;21(1):54.
Comments
